人福医药：子公司二甲磺酸利右苯丙胺胶囊药品上市许可申请获受理

Core Viewpoint - The approval of the drug registration application for Dextroamphetamine Sulfate Capsules by the National Medical Products Administration marks a significant step for the company, indicating the product is entering the review phase, which could enhance the company's product line and market competitiveness [1] Group 1 - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Dextroamphetamine Sulfate Capsules from the National Medical Products Administration [1] - Currently, there are no Dextroamphetamine Sulfate Capsules available in the domestic market, nor have any related products been approved for import [1] - The total R&D investment by Yichang Renfu in this project has reached approximately 90 million RMB [1]